|
業務類別
|
Biotechnology |
|
業務概覽
|
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron. |
| 公司地址
| 444 West Lake Street, Suite 1700, Chicago, IL, USA, 60606 |
| 電話號碼
| +1 312 416-8592 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.maiabiotech.com |
| 員工數量
| 13 |
| Mr. Jeffrey C. Himmelreich, M.B.A. |
Head, Finance and Principal Financial and Accounting Officer |
美元 272.92K |
07/04/2026 |
| Dr. Sergei M. Gryaznov, PhD |
Chief Scientific Officer |
美元 478.50K |
07/04/2026 |
| Dr. Vlad Vitoc, M.B.A.,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 612.33K |
07/04/2026 |
|
|
| Mr. Jean-Manasse Theagene |
Independent Director |
07/04/2026 |
| Dr. Stan V. Smith, PhD |
Lead Independent Director |
07/04/2026 |
| Ms. Louie Ngar Yee |
Independent Director |
07/04/2026 |
| Mr. Cristian Luput |
Independent Director |
07/04/2026 |
| Mr. Ramiro Guerrero, J.D.,L.L.M. |
Independent Director |
07/04/2026 |
| Dr. Vlad Vitoc, M.B.A.,M.D. |
Chairman of the Board, President and Chief Executive Officer |
07/04/2026 |
| Mr. Steven M. Chaouki |
Independent Director |
07/04/2026 |
|
|
|
|
